DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Andrew drives the strategic direction of the team, builds and maintains long-term strategic partnerships with clients, and translates domain knowledge into substantial value for the department.

Andrew Merron, Ph.D is the Therapy Lead for oncology and biosimilars at Decision Resources. In this capacity he is responsible for the team delivering high quality, timely, and relevant insights and forecasts. In addition, Andrew drives the strategic direction of the team, builds and maintains long-term strategic partnerships with clients, and translates domain knowledge into substantial value for the department.

Previously, Dr. Merron managed the Biosimilars Advisory Service at Decision Resources; the Biosimilars Advisory Service spans multiple therapy areas including multiple oncology indications. Prior to managing the Biosimilars Advisory Service, Dr. Merron was a principal analyst in the oncology group at Decision Resources. He has extensive experience in forecasting oncology and hematology-oncology drug markets as well as considerable experience in conducting primary research with physicians and payers across the major pharmaceutical markets. Prior to joining Decision Resources, Dr. Merron received his first-class B.Sc. degree in biochemistry from the University of Bath and his Ph.D. in molecular oncology from the University of London. His doctorate focused on in vivo molecular imaging of cancer immunotherapies, specifically therapeutic oncolytic adenoviruses.